SAN FRANCISCO--(BUSINESS WIRE)--VIA Pharmaceuticals, Inc. (NASDAQ: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that, as expected, it received a letter dated June 7, 2007 from The NASDAQ Stock Market formally notifying the Company that it did not demonstrate compliance with the recently adopted $15 million market value of publicly held shares requirement (the “Minimum Public Float Rule”) upon consummation of its merger with Corautus Genetics Inc., as required by NASDAQ Marketplace Rules 4340 and 4310(c)(2)(A)(ii).
